Evaxion significantly expands vaccine development collaboration with msd

Copenhagen, denmark, sept. 26, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced that it has entered into an option and license agreement with msd (tradename of merck & co., inc., rahway, nj, usa) for two preclinical vaccine candidates. the agreement expands the companies' current collaboration and carries significant value for evaxion.
EVAX Ratings Summary
EVAX Quant Ranking